MX2021014818A - Anticuerpos monoclonales anti-cd303. - Google Patents

Anticuerpos monoclonales anti-cd303.

Info

Publication number
MX2021014818A
MX2021014818A MX2021014818A MX2021014818A MX2021014818A MX 2021014818 A MX2021014818 A MX 2021014818A MX 2021014818 A MX2021014818 A MX 2021014818A MX 2021014818 A MX2021014818 A MX 2021014818A MX 2021014818 A MX2021014818 A MX 2021014818A
Authority
MX
Mexico
Prior art keywords
antibodies
plasmacytoid dendritic
monoclonal antibodies
bpdcn
chimeric
Prior art date
Application number
MX2021014818A
Other languages
English (en)
Inventor
Alexandre Fontayne
Nathalie Fournier
Romeuf Christophe De
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54937151&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021014818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2021014818A publication Critical patent/MX2021014818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La invención se relaciona a anticuerpos anti-CD303 quiméricos o humanizados para ácidos nucleicos que codifican para las cadenas pesadas y ligeras de estos anticuerpos, vectores de expresión, células hospedero, animales no humanos transgénicos o plantas transgénicas que expresan los anticuerpos, así como también a los usos de los mismos en el tratamiento o prevención de neoplasma de células dendríticas plasmacitoides blásticas (BPDCN) o enfermedades inflamatorias, en particular enfermedades autoinmunológicas, que implican células dendríticas plasmacitoides.
MX2021014818A 2015-03-31 2017-09-27 Anticuerpos monoclonales anti-cd303. MX2021014818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1552757A FR3034420A1 (fr) 2015-03-31 2015-03-31 Anticorps monoclonaux anti-cd303

Publications (1)

Publication Number Publication Date
MX2021014818A true MX2021014818A (es) 2022-01-18

Family

ID=54937151

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012399A MX2017012399A (es) 2015-03-31 2016-03-31 Anticuerpos monoclonales anti-cd303.
MX2021014818A MX2021014818A (es) 2015-03-31 2017-09-27 Anticuerpos monoclonales anti-cd303.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012399A MX2017012399A (es) 2015-03-31 2016-03-31 Anticuerpos monoclonales anti-cd303.

Country Status (13)

Country Link
US (3) US10239946B2 (es)
EP (2) EP3277723B1 (es)
JP (2) JP2018511328A (es)
KR (1) KR20170132819A (es)
CN (1) CN107660212A (es)
AR (1) AR104156A1 (es)
AU (1) AU2016239936A1 (es)
BR (1) BR112017020698A2 (es)
CA (1) CA2981093A1 (es)
ES (1) ES2819902T3 (es)
FR (2) FR3034420A1 (es)
MX (2) MX2017012399A (es)
WO (2) WO2016156450A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) † 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3045386B1 (fr) * 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
FR3060394B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
FR3060395B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
US11701387B2 (en) * 2018-01-04 2023-07-18 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for BDCA2 antigen
SG11202112553WA (en) * 2019-06-13 2021-12-30 Allogene Therapeutics Inc Anti-talen antibodies and uses thereof
CN114516915B (zh) * 2020-11-19 2023-03-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体以及制备抗体的方法
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用
CN116693687B (zh) * 2023-08-03 2023-10-03 天津旷博同生生物技术有限公司 一种抗人cd25工程抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
JP4523165B2 (ja) 1998-11-02 2010-08-11 トラスティーズ オブ タフツ カレッジ トランスジェニックおよびクローン哺乳動物
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
BR0014860A (pt) 1999-10-14 2003-07-08 Genzyme Transgenics Corp Métodos para a produção de uma molécula alvo em um animal transgênico e purificação da molécula alvo
CA2664137C (en) * 1999-11-15 2012-09-25 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
AU2003298787A1 (en) 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP2007507232A (ja) 2003-09-30 2007-03-29 スターンベルド バイオテクノロジー ノース アメリカ， インコーポレイテッド 乳汁中に外因性タンパク質を産生するトランスジェニック哺乳動物を作製するプロセスおよびそれによって産生されるトランスジェニック哺乳動物
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
AU2006304886B2 (en) 2005-10-21 2012-04-12 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
ES2620261T3 (es) 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
EP2352521B1 (en) 2008-10-14 2020-09-16 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2981946B1 (fr) 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
FR2986536A1 (fr) 2012-02-08 2013-08-09 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (cho)
US9175691B2 (en) * 2012-10-03 2015-11-03 Praxair Technology, Inc. Gas compressor control system preventing vibration damage
MX363407B (es) * 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
BR112016014920A2 (pt) * 2013-12-24 2017-12-12 Astellas Pharma Inc novo anticorpo anti-bdca-2 humano
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303

Also Published As

Publication number Publication date
US20180086834A1 (en) 2018-03-29
AU2016239936A1 (en) 2017-10-12
US20200277385A1 (en) 2020-09-03
WO2016156449A1 (fr) 2016-10-06
FR3034430A1 (fr) 2016-10-07
AR104156A1 (es) 2017-06-28
MX2017012399A (es) 2018-01-26
CA2981093A1 (fr) 2016-10-06
JP2018511328A (ja) 2018-04-26
US20180066060A1 (en) 2018-03-08
ES2819902T3 (es) 2021-04-19
BR112017020698A2 (pt) 2018-06-26
FR3034430B1 (fr) 2024-03-29
JP6829210B2 (ja) 2021-02-10
US10239946B2 (en) 2019-03-26
CN107660212A (zh) 2018-02-02
WO2016156450A1 (fr) 2016-10-06
EP3277723A1 (fr) 2018-02-07
EP3277720A1 (fr) 2018-02-07
FR3034420A1 (fr) 2016-10-07
US10611843B2 (en) 2020-04-07
KR20170132819A (ko) 2017-12-04
EP3277723B1 (fr) 2020-06-17
JP2018512144A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
MX2017006802A (es) Animales no humanos que expresan el complejo cd3 humanizado.
MX2016016903A (es) Animales no humanos que tienen un gen de muerte celular programada 1 humanizado.
MX368931B (es) Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
MY178882A (en) Non-human animals with modified immunoglobulin heavy chain sequences
MX2021000484A (es) Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph.
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
MX353609B (es) Animales no humanos que expresan anticuerpos que tienen una cadena ligera comun.
MX2017007636A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
MX361533B (es) Anticuerpos anti-cd22.
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
NZ627977A (en) Humanized rodents that express heavy chains containing vl domains
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
MX2016006513A (es) Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion.
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
PH12017501090A1 (en) Parental rnai suppression of kruppel gene to control coleopteran pests
ZA202001389B (en) Non-human animals expressing humanized c1q complex
TH1601001594A (th) สัตว์ที่ไม่ใช่มนุษย์ซึ่งมียีนโปรตีนควบคุมสัญญาณที่ได้รับการฮิวมาไนซ์